Restoring LSECtin expression in cirrhosis
Restoring LSECtin expression in cirrhosis
Disciplines
Clinical Medicine (100%)
Keywords
-
Cirrhosis,
LSEC,
Portal Hypertension,
Inflammation
Liver cirrhosis is a serious chronic disease in which healthy liver tissue is gradually replaced by scar tissue due to long-term damage (e.g., from alcohol). As a result, the liver progressively loses its function including its ability to support the immune system. Specialized cells in the livers blood vessels, known as LSEC cells, play a key role in controlling inflammation, but they lose this function in cirrhosis. A planned research project will investigate the role of a protein called LSECtin in these LSEC cells. This protein, which plays an important role in the livers immune system, is no longer produced in sufficient amounts during cirrhosis. The research will examine whether specific immune signaling molecules (interleukins 10 and 13; IL-10 and IL-13) can help restore the production of LSECtin. In a further step, the project will explore whether the production of LSECtin can be stimulated through targeted changes in the way genetic material is packaged so- called epigenetic mechanisms. A substance that directly influences these mechanisms will be used. It will be delivered to the affected cells using tiny transport particles. The project will also analyze liver tissue samples from patients with cirrhosis to compare the findings from laboratory models with real-life disease conditions. The goal is to find new ways to boost LSECtin production and thereby improve the livers immune system in cirrhosis potentially paving the way for future treatment options.
- Universidad Miguel Hernandez - 100%
Research Output
- 3 Publications
- 1 Scientific Awards
-
2025
Title Bile acid signaling in MASLD: From pathogenesis to therapeutic applications. DOI 10.1097/hep.0000000000001539 Type Journal Article Author Paternostro R Journal Hepatology (Baltimore, Md.) -
2026
Title Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease. DOI 10.1111/apt.70407 Type Journal Article Author Simbrunner B Journal Alimentary pharmacology & therapeutics Pages 648-661 -
2025
Title Antagonizing epigenetically controlled PAF/PAF-R pathway improves liver function during experimental cirrhosis. DOI 10.1016/j.biopha.2025.118804 Type Journal Article Author Caparrós E Journal Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pages 118804
-
2025
Title 3nd INTERNATIONAL WORKSHOP ON LIVER AND GUT FIBROSIS Type Personally asked as a key note speaker to a conference Level of Recognition Continental/International